학술논문

Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
Document Type
Journal
Source
ANNALS OF ONCOLOGY; 2021, 32 pS951-pS952, 3p. Supplement: 5
Subject
Language
English
ISSN
15698041